
    
      This is a single-centre, 2-part, open-label, non-randomised, sequential, single dose study in
      healthy male subjects. It is planned to enrol a single cohort of 6 healthy male subjects who
      will participate in Parts 1 and Part 2 of the study.

      In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV
      microtracer dose of [14C]-SK-1404.

      In Part 2, each subject will receive a single PO dose of [14C]-SK-1404.
    
  